Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient

Gomathi, T.; Govindarajan, C.; Rose, H H R Maximas; Sudha, P.N.; Imran, P.K.M.; Venkatesan, Jayachandran; Kim, Se‐Kwon

doi:10.1016/j.ijpharm.2014.04.026

Cited by 45 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar pattern has been observed by Li et al [25] with incorporation of cellulose nanowhiskers in PVA, the 2θ was lowered. They also reproted Gomathi et al [26] on XRD of chitosan nanoparticle obtained a broad peak at 18.35° due to formation of chitosan nanoparticle, as comapred to chitosan which had a peak at 19.5°. This shift is due to the amorphous nature of cross linking of hydrogen bonds in chitosan, sodium hexaphosphate and lenalidomide used in their study.…”

Section: Resultsmentioning

confidence: 77%

Mechanical and Structural Characterization of Eco-Friendly Films Prepared Using Poly(vinyl alcohol), Cellulose Nanocrystals and Chitosan Nanoparticle Blend

Dey¹,

Selvam²,

Kumar³

et al. 2017

Asian J. Chem.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 77%

Mechanical and Structural Characterization of Eco-Friendly Films Prepared Using Poly(vinyl alcohol), Cellulose Nanocrystals and Chitosan Nanoparticle Blend

Dey¹,

Selvam²,

Kumar³

et al. 2017

Asian J. Chem.

View full text Add to dashboard Cite

“…In vitro release studies (Gomathi et al, 2014) The dialysis bag diffusion technique was incorporated to analyze the in vitro drug release of LND from NPs. The drug loaded NPs were placed in the dialysis bag (3 mL) and immersed into 250 mL of HCl buffer (pH 1.2) for a period of 48 h. The receptor phase was stirred and the temperature was maintained at 37 °C.…”

Section: Analytical Conditionsmentioning

confidence: 99%

Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma

Karri

Dhandapani

Mannemala

et al. 2017

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Lenalidomide (LND) is an anti-cancer drug and an effective derivative of thalidomide used for multiple myeloma therapy. Because of its poor solubility in water, LND is known to cause low oral bioavailability (below 33%), and as a direct consequence of this, the dosing frequency is extended thus increasing risk of toxicity. To improve its bioavailability and sustained release, the present study aims to formulate polymeric nanoparticles (NPs) for LND using [Poly (lactic-co-glycolic acid)] (PLGA) as a polymer. The polymeric NPs were evaluated for particle size, SEM, XRD, drug content, entrapment efficiency (EE), in vitro release studies and in vivo bioavailability studies in rats. The formulated NPs possessed a size of 179±0.9 nm and a zeta potential of -24.4 ± 0.2 mV. The drug loading and EE of the optimized formulation was 32 ± 0.37 % and 78 ± 0.92% respectively. After oral administration of LND PLGA-NPs, the relative bioavailability was enhanced about 3.67-fold compared to LND. This study demonstrates the novel drug delivery for LND with PLGA-NPs as effective drug delivery system for sustained delivery of LND. Uniterms:Multiple myeloma/treatment. Lenalidomide/uses. PLGA/sustained release. Polymeric nanoparticles/development. Solubility.

show abstract

“…The chitosan of 0.02% w/v was dissolved in a solution of 0.1% v/v acetic acid was kept under magnetic stirring and pH of the solution was adjusted to 5.5 using 1N sodium hydroxide, a constant amount of cefixime 0.05% (w/v) was added to the chitosan solution with constant stirring at 3500 rpm. The gum solution was added slowly drop wise to the mixture of chitosan and cefixime at a different polymeric ratios to give four different formulations i.e., F1 (1:1), F2 (2:1), F3 (1:2), F4 (2:2) by modified coacervation method at 12000 rpm for 45 min and then freeze dried and the nanoparticles were stored in desiccator 19,20 .…”

Section: Preparation Of Cefixime Nanoparticlesmentioning

confidence: 99%

Untitled

2016

IJPSR

View full text Add to dashboard Cite

ABSTRACT:Cefixime is more effective in treating multi drug resistant typhoid fever but the major limitation was its poor bioavailability with short half-life. The present investigation was attempted to develop a natural polymer based nanoparticles containing cefixime using gum kondagogu and chitosan as polymers for customising the drug release profile to achieve an effective therapeutic concentration by increasing its solubility and bioavailability. The cefixime nanoparticles were prepared by the modified coacervation method and evaluated for particle size, zeta potential, morphological studies (SEM, TEM and AFM), entrapment efficiency, invitro drug release studies and in-vitro antimicrobial efficiency studies. The prepared drug nanoparticles found to be average mean particle size in range from 80.6±3.5 to 230.6±7.3nm and entrapment efficiency was found to be 78.0±1.5 to 93.2±2.5%. The in-vitro drug release showed a biphasic pattern with initial burst release followed by sustained drug release up to 32h. The MIC50 of prepared formulation was one fold lesser than pure cefixime for Salmonella Typhi isolates. The disc agar diffusion (DAD) test confers that the zone of inhibition was found to be better for the formulation against pure cefixime. In conclusion, the developed Cefixime nanoparticles support to customise the drug release profile and better zone of inhibition with minimum concentration which provoke better patient compliance.

show abstract

Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient

Cited by 45 publications

References 35 publications

Mechanical and Structural Characterization of Eco-Friendly Films Prepared Using Poly(vinyl alcohol), Cellulose Nanocrystals and Chitosan Nanoparticle Blend

Mechanical and Structural Characterization of Eco-Friendly Films Prepared Using Poly(vinyl alcohol), Cellulose Nanocrystals and Chitosan Nanoparticle Blend

Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma

Untitled

Contact Info

Product

Resources

About